{"disease":{"id":"diabete-mellitus","name":"diabete mellitus"},"drugs":{"marketed":[{"drug_id":"semaglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ozempic","generic_name":"semaglutide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":90,"revenue":"27400","mechanism":"Semaglutide, a GLP-1 analogue, lowers blood glucose by stimulating insulin and inhibiting glucagon secretion in a glucose-dependent manner, and delays gastric emptying."},{"drug_id":"tirzepatide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mounjaro","generic_name":"TIRZEPATIDE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"GIP receptor and GLP-1 receptor","drug_class":"Dual GIP/GLP-1 receptor agonist","quality_score":84,"revenue":"15530","mechanism":"Tirzepatide is a dual GIP and GLP-1 receptor agonist with C20 fatty diacid for albumin binding."},{"drug_id":"aflibercept","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"dulaglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trulicity","generic_name":"DULAGLUTIDE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":63,"revenue":"7200","mechanism":"Dulaglutide activates GLP-1 receptors, increasing insulin release and decreasing glucagon secretion and gastric emptying."},{"drug_id":"empagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jardiance","generic_name":"empagliflozin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":66,"revenue":"6500","mechanism":"SYNJARDY combines empagliflozin, which inhibits SGLT2 to increase urinary glucose excretion, and metformin HCl, which improves glucose tolerance and insulin sensitivity."},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or functional or anatomical asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"dapagliflozin","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farxiga","generic_name":"DAPAGLIFLOZIN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":69,"revenue":"6300","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine."},{"drug_id":"dapagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farxiga","generic_name":"DAPAGLIFLOZIN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":69,"revenue":"6300","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine."},{"drug_id":"faricimab","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vabysmo","generic_name":"FARICIMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":62,"revenue":"5500","mechanism":"Vabysmo works by blocking the activity of a protein called vascular endothelial growth factor A."},{"drug_id":"insulin-glargine","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lantus","generic_name":"INSULIN GLARGINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":70,"revenue":"4800","mechanism":"Lantus works by mimicking the action of natural insulin to lower blood sugar levels."},{"drug_id":"insulin-glargine","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lantus","generic_name":"INSULIN GLARGINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":70,"revenue":"4800","mechanism":"Lantus works by mimicking the action of natural insulin to lower blood sugar levels."},{"drug_id":"insulin-degludec","indication_name":"Diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tresiba","generic_name":"INSULIN DEGLUDEC","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":10,"revenue":"4500","mechanism":"Tresiba works by binding to the insulin receptor, mimicking the action of natural insulin to lower blood sugar levels."},{"drug_id":"sitagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Januvia","generic_name":"SITAGLIPTIN","company_name":"Zydus Lifesciences","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":75,"revenue":"3200","mechanism":"Januvia works by blocking an enzyme that breaks down hormones that help the body release insulin."},{"drug_id":"liraglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Victoza","generic_name":"liraglutide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":35,"revenue":"3200","mechanism":null},{"drug_id":"insulin-aspart","indication_name":"Diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novolog","generic_name":"INSULIN ASPART","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":62,"revenue":"2800","mechanism":"Novolog works by binding to the insulin receptor, triggering a cascade of cellular responses that lower blood glucose levels."},{"drug_id":"insulin-lispro","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humalog","generic_name":"INSULIN LISPRO","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":70,"revenue":"2200","mechanism":"Humalog works by mimicking the natural hormone insulin to help cells absorb glucose from the bloodstream."},{"drug_id":"insulin-lispro","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humalog","generic_name":"INSULIN LISPRO","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":70,"revenue":"2200","mechanism":"Humalog works by mimicking the natural hormone insulin to help cells absorb glucose from the bloodstream."},{"drug_id":"linagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tradjenta","generic_name":"LINAGLIPTIN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":75,"revenue":"800","mechanism":"Tradjenta works by blocking an enzyme that breaks down hormones that help the body release insulin."},{"drug_id":"bi-1356","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tradjenta","generic_name":"BI 1356","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":71,"revenue":"800","mechanism":"Tradjenta works by blocking the DPP-4 enzyme, which normally breaks down incretin hormones that help regulate blood sugar levels."},{"drug_id":"canagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invokana","generic_name":"CANAGLIFLOZIN","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":71,"revenue":"800","mechanism":"Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption."},{"drug_id":"vildagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jalra","generic_name":"VILDAGLIPTIN","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"vildagliptin","quality_score":37,"revenue":"159","mechanism":""},{"drug_id":"acarbose","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Precose","generic_name":"ACARBOSE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Sucrase-isomaltase, intestinal","drug_class":"alpha-Glucosidase Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"chlorpropamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diabinese","generic_name":"CHLORPROPAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"carbutamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Burcol","generic_name":"CARBUTAMIDE","company_name":"","drug_phase":"phase_2","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"carbutamide","quality_score":null,"revenue":null,"mechanism":"Burcol works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."},{"drug_id":"acetohexamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dymelor","generic_name":"ACETOHEXAMIDE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"acetohexamide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"bexagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brenzavvy","generic_name":"BEXAGLIFLOZIN","company_name":"Theracosbio","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":58,"revenue":null,"mechanism":"Bexagliflozin inhibits SGLT2 to reduce renal glucose reabsorption and increase urinary glucose excretion."},{"drug_id":"metformin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucophage","generic_name":"metformin","company_name":"Generic (originally Merck Serono/Lipha)","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia."},{"drug_id":"metformin","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucophage","generic_name":"metformin","company_name":"Generic (originally Merck Serono/Lipha)","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia."},{"drug_id":"dasiglucagon","indication_name":"Hypoglycemia due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zegalogue","generic_name":"DASIGLUCAGON","company_name":"Zealand Pharma","drug_phase":"marketed","molecular_target":"Glucagon receptor","drug_class":"Antihypoglycemic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Zegalogue works by stimulating the release of glucose from stored energy sources in the body."},{"drug_id":"ertugliflozin-15-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 15 mg","generic_name":"ertugliflozin-15-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"januvia","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Januvia","company_name":"Johns Hopkins University","drug_phase":"discontinued","molecular_target":"Dipeptidyl peptidase 2, Dipeptidyl peptidase 8, Dipeptidyl peptidase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"duvie","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"duvie","company_name":"Pusan National University Hospital","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"liraglutid","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Liraglutid","company_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"pioglitazone","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actos","generic_name":"pioglitazone","company_name":"Takeda","drug_phase":"marketed","molecular_target":"CDGSH iron-sulfur domain-containing protein 2, Bile salt export pump, CDGSH iron-sulfur domain-containing protein 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"saxenda","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Saxenda","company_name":"Seoul National University Hospital","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"telmisartan","indication_name":"Disorder due to type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micardis","generic_name":"TELMISARTAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Type-2 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"victoza","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Victoza","company_name":"Hanmi Pharmaceutical Company Limited","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"eylea","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"glucophage","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glucophage","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"glucophage","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glucophage","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"glipizide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucotrol","generic_name":"GLIPIZIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea [EPC]","quality_score":62,"revenue":null,"mechanism":"Glucotrol works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."},{"drug_id":"lantus","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lantus","company_name":"Rijnstate Hospital","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"lantus","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lantus","company_name":"Rijnstate Hospital","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"apidra","indication_name":"Diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Apidra","company_name":"Kinderkrankenhaus auf der Bult","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"faricimab-svoa","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"VABYSMO","generic_name":"FARICIMAB-SVOA","company_name":"GENENTECH INC","drug_phase":"marketed","molecular_target":"Angiopoietin-2, Vascular endothelial growth factor A","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"lucentis","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mitiglinide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MITIGLINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"mitiglinide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tofogliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apleway","generic_name":"TOFOGLIFLOZIN","company_name":"","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"benfluorex","indication_name":"Type 2 diabetes mellitus in obese","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benfluramate","generic_name":"BENFLUOREX","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"benfluorex","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"gliclazide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diabyl","generic_name":"GLICLAZIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"gliclazide","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"lobeglitazone","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duvie","generic_name":"LOBEGLITAZONE","company_name":"Chong Kun Dang","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor gamma","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"levemir","indication_name":"Diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Levemir","company_name":"The Royal Bournemouth Hospital","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"lyumjev","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lyumjev","company_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"lyumjev","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lyumjev","company_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"teplizumab-mzwv","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TZIELD","generic_name":"TEPLIZUMAB-MZWV","company_name":"PROVENTION BIO INC","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"CD3-directed Antibody [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"dapa","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPA","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"dapa","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPA","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"nateglinide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Starlix","generic_name":"NATEGLINIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Glinide [EPC]","quality_score":75,"revenue":null,"mechanism":"Starlix works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."},{"drug_id":"glymidine","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gondafon","generic_name":"GLYMIDINE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"glymidine","quality_score":null,"revenue":null,"mechanism":"Gondafon works by stimulating insulin release from the pancreas."},{"drug_id":"voglibose","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glustat","generic_name":"VOGLIBOSE","company_name":"","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"voglibose","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"exenatide","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Byetta","generic_name":"EXENATIDE","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Byetta works by mimicking the action of a natural hormone in the body to regulate blood sugar levels."},{"drug_id":"alogliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nesina","generic_name":"ALOGLIPTIN","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor","quality_score":65,"revenue":null,"mechanism":"Nesina works by blocking an enzyme that breaks down incretin hormones, allowing more insulin to be released and less glucagon."},{"drug_id":"colesevelam","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welchol","generic_name":"COLESEVELAM","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant","quality_score":10,"revenue":null,"mechanism":"Welchol works by binding to bile acids in the gut, reducing their reabsorption and increasing their excretion, which in turn lowers cholesterol levels and improves blood sugar control."},{"drug_id":"repaglinide","indication_name":"Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prandin","generic_name":"repaglinide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family C member 8","drug_class":"Glinide [EPC]","quality_score":10,"revenue":null,"mechanism":"Repaglinide lowers blood glucose levels by stimulating insulin release from the pancreas through ATP-dependent potassium channel blockade."},{"drug_id":"repaglinide","indication_name":"Not for treatment of type 1 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prandin","generic_name":"repaglinide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family C member 8","drug_class":"Glinide [EPC]","quality_score":10,"revenue":null,"mechanism":"Repaglinide lowers blood glucose levels by stimulating insulin release from the pancreas through ATP-dependent potassium channel blockade."},{"drug_id":"insulin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humulin","generic_name":"insulin","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Lck","drug_class":"Insulin Analog [EPC]","quality_score":60,"revenue":null,"mechanism":"Humulin works by binding to insulin receptors on cells, triggering a cascade of signals that lower blood glucose levels."},{"drug_id":"ertugliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Steglatro","generic_name":"ERTUGLIFLOZIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter","drug_class":"","quality_score":54,"revenue":null,"mechanism":"Steglatro works by blocking the kidneys' ability to reabsorb glucose, allowing excess glucose to be excreted in the urine."},{"drug_id":"insulin","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humulin","generic_name":"insulin","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Lck","drug_class":"Insulin Analog [EPC]","quality_score":60,"revenue":null,"mechanism":"Humulin works by binding to insulin receptors on cells, triggering a cascade of signals that lower blood glucose levels."},{"drug_id":"brolucizumab","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beovu","generic_name":"BROLUCIZUMAB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Beovu works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and reducing vascular permeability and inflammation."},{"drug_id":"insulin-detemir","indication_name":"Diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levemir","generic_name":"INSULIN DETEMIR","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Levemir works by binding to the insulin receptor, triggering a response that lowers blood sugar levels."},{"drug_id":"lixisenatide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adlyxin","generic_name":"LIXISENATIDE","company_name":"Sanofi-Aventis Us Llc","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"Insulin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Adlyxin works by mimicking the action of the GLP-1 hormone to help regulate blood sugar levels."},{"drug_id":"ertugliflozin-5-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 5 mg","generic_name":"ertugliflozin-5-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or alcoholism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"sotagliflozin","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"sotagliflozin","indication_name":"Diabetes mellitus type 2 at increased risk of cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"buformin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butformin","generic_name":"BUFORMIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"buformin","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"troglitazone","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezulin","generic_name":"TROGLITAZONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Forkhead box protein M1","drug_class":"troglitazone","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tolbutamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aglicid","generic_name":"TOLBUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"insulin-glulisine","indication_name":"Diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apidra","generic_name":"INSULIN GLULISINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":55,"revenue":null,"mechanism":"Insulin glulisine lowers blood glucose by stimulating glucose uptake in muscles and fat, and by inhibiting liver glucose production."},{"drug_id":"albiglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Albugon","generic_name":"ALBIGLUTIDE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"byetta","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Byetta","generic_name":"Byetta","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Byetta works by activating the glucagon-like peptide 1 receptor, which helps regulate blood sugar levels."},{"drug_id":"miglitol","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glyset","generic_name":"MIGLITOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"alpha-Glucosidase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Glyset works by delaying the breakdown of carbohydrates in the gut, allowing less glucose to enter the bloodstream."},{"drug_id":"pramlintide","indication_name":"Type 1 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symlin","generic_name":"PRAMLINTIDE","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"pramlintide","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symlin","generic_name":"PRAMLINTIDE","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"forxiga","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Forxiga","company_name":"AstraZeneca Turkey","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"forxiga","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Forxiga","company_name":"AstraZeneca Turkey","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"jardiance","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Jardiance","company_name":"University of Louisville","drug_phase":"marketed","molecular_target":"Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"novolog","indication_name":"Diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Novolog","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"farxiga","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farxiga","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"farxiga","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farxiga","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"beovu","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beovu","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rybelsus","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rybelsus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bydureon","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bydureon","company_name":"Phoenix VA Health Care System","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor, Glucagon-like peptide 1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pritor","indication_name":"Disorder due to type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pritor","company_name":"DongKoo Bio & Pharma","drug_phase":"phase_1","molecular_target":"ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"welchol","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Welchol","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bromocriptin","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bromocriptin","company_name":"University Hospital, Bonn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"humalog","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humalog","company_name":"Halozyme Therapeutics","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"humalog","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humalog","company_name":"Halozyme Therapeutics","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mounjaro","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mounjaro","company_name":"Nicholas Skertich","drug_phase":"marketed","molecular_target":"Gastric inhibitory polypeptide receptor, Glucagon-like peptide 1 receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"sitagliptin-and-metformin","indication_name":"Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"sitagliptin and metformin","company_name":"University Medical Centre Ljubljana","drug_phase":"marketed","molecular_target":"","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":22,"revenue":null,"mechanism":null},{"drug_id":"ranibizumab-nuna","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"nateglinide","indication_name":"Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Starlix","generic_name":"NATEGLINIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Glinide [EPC]","quality_score":75,"revenue":null,"mechanism":"Starlix works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."},{"drug_id":"caduet","indication_name":"Type 2 Diabetes Mellitus with multiple risk factors for CHD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"gemigliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zemiglo","generic_name":"GEMIGLIPTIN","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"gemigliptin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"anagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suiny","generic_name":"ANAGLIPTIN","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"ipragliflozin","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suglat","generic_name":"IPRAGLIFLOZIN","company_name":"","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"ipragliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suglat","generic_name":"IPRAGLIFLOZIN","company_name":"","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"glisoxepide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glisepin","generic_name":"GLISOXEPIDE","company_name":"","drug_phase":"phase_2","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"glisoxepide","quality_score":28,"revenue":null,"mechanism":"Glisoxepide works by blocking potassium channels in the pancreas, allowing more insulin to be released."},{"drug_id":"dapaglifozin","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dapaglifozin","company_name":"MedImmune LLC","drug_phase":"phase_3","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"dapaglifozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dapaglifozin","company_name":"MedImmune LLC","drug_phase":"phase_3","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"evogliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suganon","generic_name":"EVOGLIPTIN","company_name":"Dong-A ST","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"glibenclamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micronase","generic_name":"glibenclamide","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"glibenclamide","indication_name":"Neonatal diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micronase","generic_name":"glibenclamide","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"imeglimin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Twymeeg","generic_name":"IMEGLIMIN","company_name":"SUMITOMO DAINIPPON PHARMA Co., Ltd.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"tradjenta","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tradjenta","company_name":"EMS","drug_phase":"discontinued","molecular_target":"Dipeptidyl peptidase 9, Prolyl endopeptidase FAP, Dipeptidyl peptidase 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"saroglitazar","indication_name":"Diabetic dyslipidemia associated with type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipaglyn","generic_name":"SAROGLITAZAR","company_name":"Cadila Healthcare","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"teplizumab","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tzield","generic_name":"TEPLIZUMAB","company_name":"Provention Bio Inc","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"CD3-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Tzield works by binding to the CD3 complex on T-cells, preventing them from attacking pancreatic beta cells."},{"drug_id":"bromocriptine","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parlodel","generic_name":"BROMOCRIPTINE","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Ergot Derivative","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"glimepiride","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amaryl","generic_name":"GLIMEPIRIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea [EPC]","quality_score":62,"revenue":null,"mechanism":"Amaryl works by binding to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, closing the channel and depolarizing the pancreatic beta cell membrane, leading to insulin release."},{"drug_id":"glimepiride","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amaryl","generic_name":"GLIMEPIRIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea [EPC]","quality_score":62,"revenue":null,"mechanism":"Amaryl works by binding to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, closing the channel and depolarizing the pancreatic beta cell membrane, leading to insulin release."},{"drug_id":"rosiglitazone","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avandia","generic_name":"ROSIGLITAZONE","company_name":"Woodward","drug_phase":"marketed","molecular_target":"CDGSH iron-sulfur domain-containing protein 1","drug_class":"Peroxisome Proliferator Receptor gamma Agonist","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":121,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06239129","title":"The Stockholm CREAtinine Measurements Project","phase":"","overall_status":"COMPLETED","enrollment_count":3200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT02958995","title":"Epidemiologic Study Of Diabetes And Cancer Risk","phase":"","overall_status":"COMPLETED","enrollment_count":2738161,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05285085","title":"Real World Evidence Study of Statin Use in Brazil","phase":"","overall_status":"COMPLETED","enrollment_count":2133900,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT07126041","title":"Scalable Public Health Empowerment, Research, and Education Sites (SPHERES)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1750000,"lead_sponsor_name":"Oxford University Clinical Research Unit Indonesia","has_results":false},{"nct_id":"NCT04017221","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":1249636,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT03811470","title":"China Diabetes Registry by Metabolic Management Center","phase":"","overall_status":"RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Guang Ning","has_results":false},{"nct_id":"NCT05813652","title":"Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1","phase":"","overall_status":"COMPLETED","enrollment_count":919928,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT03492580","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":714582,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04572165","title":"Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data","phase":"","overall_status":"UNKNOWN","enrollment_count":600000,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05161429","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","phase":"","overall_status":"UNKNOWN","enrollment_count":550000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05882071","title":"Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":547150,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05730582","title":"Increasing Uptake of EHR-enabled Population Health Outreach Strategies to Improve Diabetes Screening","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500000,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT05162014","title":"To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin","phase":"","overall_status":"COMPLETED","enrollment_count":494679,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04927858","title":"A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017","phase":"","overall_status":"COMPLETED","enrollment_count":460558,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06913153","title":"Tianjin Diabetes and Health Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":396983,"lead_sponsor_name":"Tianjin Medical University","has_results":true},{"nct_id":"NCT03464045","title":"Empa PASS on Urinary Tract Malignancies","phase":"","overall_status":"COMPLETED","enrollment_count":344995,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05004428","title":"A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)","phase":"","overall_status":"COMPLETED","enrollment_count":336376,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02864914","title":"Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":333580,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03817463","title":"A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":327624,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06330480","title":"Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":320000,"lead_sponsor_name":"Prof. Dr. Folkert W. Asselbergs","has_results":false},{"nct_id":"NCT05248412","title":"The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":250000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT05073692","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","phase":"","overall_status":"COMPLETED","enrollment_count":241981,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT06099067","title":"Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)","phase":"","overall_status":"COMPLETED","enrollment_count":239990,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02958956","title":"Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.","phase":"","overall_status":"COMPLETED","enrollment_count":236507,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03363464","title":"Comparative Effectiveness of Empagliflozin in the US","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT03330301","title":"D-tecting Disease - From Exposure to Vitamin D During Critical Periods of Life","phase":"","overall_status":"COMPLETED","enrollment_count":222776,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT07513259","title":"Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":203424,"lead_sponsor_name":"Chung Shan Medical University","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT07198191","title":"SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT02636192","title":"Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02197078","title":"Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin","phase":"","overall_status":"COMPLETED","enrollment_count":189426,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03092752","title":"Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV","phase":"","overall_status":"COMPLETED","enrollment_count":162116,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06659744","title":"Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims","phase":"","overall_status":"COMPLETED","enrollment_count":158310,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05524792","title":"Incidence of Diabetes After a COVID-19 Infection","phase":"","overall_status":"COMPLETED","enrollment_count":157134,"lead_sponsor_name":"InGef - Institute for Applied Health Research Berlin GmbH","has_results":false},{"nct_id":"NCT06608212","title":"An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03299010","title":"10-year Risk Prediction Models of Complications and Mortality of DM in Hong Kong","phase":"","overall_status":"COMPLETED","enrollment_count":141516,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT02857764","title":"Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":127690,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06784713","title":"DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN","phase":"","overall_status":"COMPLETED","enrollment_count":127277,"lead_sponsor_name":"University of Tartu","has_results":false},{"nct_id":"NCT06251323","title":"Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)","phase":"NA","overall_status":"RECRUITING","enrollment_count":119680,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT06883318","title":"Physical, Psychological and Socioeconomic Effects of Childhood Onset Diabetes in Sweden","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":115000,"lead_sponsor_name":"Umeå University","has_results":false},{"nct_id":"NCT06769646","title":"SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data","phase":"","overall_status":"COMPLETED","enrollment_count":110074,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04302974","title":"Cohort Study on Patient Outcomes, Effectiveness and Cost-effectiveness of Intervention Programmes for DM/HT Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT07307183","title":"Prediction Model for the Risk of Developing Foot Ulcers in Diabetes","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT04229628","title":"Hypertension and Diabetes Mellitus Community Management Center(HAD-COME) Project","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT00342927","title":"Family Investigation of Nephropathy and Diabetes (F.I.N.D.)","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT02993614","title":"Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":99999,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02713321","title":"Impact of Medicaid Health Home on Patients With Diabetes in New York City","phase":"","overall_status":"COMPLETED","enrollment_count":96759,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":true},{"nct_id":"NCT06913881","title":"Comparative Cardiovascular Effectiveness of GLP-1 RAs vs. Insulin in Early-Onset Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":92100,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03677609","title":"Stanford Clinics Physician Mindset Training","phase":"NA","overall_status":"COMPLETED","enrollment_count":78128,"lead_sponsor_name":"Kari Alyse Leibowitz","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}